PRILENIA
Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a n oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. The company was founded in 2018 and is based in Israel, the Netherlands, and Boston.
PRILENIA
Industry:
Biotechnology Health Care Life Science Pharmaceutical
Founded:
2018-01-01
Address:
Herzliya, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.prilenia.com
Total Employee:
11+
Status:
Active
Contact:
+972-77-5558482
Email Addresses:
[email protected]
Total Funding:
105.5 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome IPv6 Organization Schema Google Universal Analytics
Similar Organizations
Apic Bio
Apic Bio is a gene therapy company that develops treatment options for rare, undertreated neurological and liver diseases.
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
OncoHost
OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy.
SSTKBIO
SSTKBIO is a laboratory that develops early detection and early intervention technology for the tumor.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Wave Life Sciences
Wave Life Sciences is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling diseases
Current Advisors List
Current Employees Featured
Founder
Investors List
Sectoral Asset Management
Sectoral Asset Management investment in Series B - Prilenia
Talisman Capital Partners
Talisman Capital Partners investment in Series B - Prilenia
Forbion Capital Partners
Forbion Capital Partners investment in Series B - Prilenia
ALS Investment Fund
ALS Investment Fund investment in Series B - Prilenia
Amplitude Venture Capital
Amplitude Venture Capital investment in Series B - Prilenia
Sands Capital Ventures
Sands Capital Ventures investment in Series B - Prilenia
Morningside Venture Partners
Morningside Venture Partners investment in Series B - Prilenia
Forbion Capital Partners
Forbion Capital Partners investment in Series A - Prilenia
Morningside Venture Investments
Morningside Venture Investments investment in Series A - Prilenia
Sectoral Asset Management
Sectoral Asset Management investment in Series A - Prilenia
Key Employee Changes
| Date | New article |
|---|---|
| 2022-09-29 | Prilenia Expands Leadership Team, Appoints Anne Sullivan as Chief Business Officer |
| 2020-06-03 | Prilenia Therapeutics raises $62.5m, names Michael Hayden CEO |
Official Site Inspections
http://www.prilenia.com Semrush global rank: 4.41 M Semrush visits lastest month: 2.21 K
- Host name: 230.43.214.35.bc.googleusercontent.com
- IP address: 35.214.43.230
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Prilenia"
Prilenia Therapeutics: A Clinical Stage Biotech Company
Prilenia is dedicated to developing new treatments for the urgent needs facing patients and families with Huntington’s disease, amyotrophic lateral sclerosis (ALS), and other …See details»
Meet the Team at Prilenia
Limor also serves as CEO of Prilenia’s Israeli entity, Prilenia Neurotherapeutics Ltd. Limor has more than 20 years of experience in strategy, planning, and operations. Prior to joining Prilenia …See details»
Prilenia - Crunchbase Company Profile & Funding
Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a n oral drug candidate with …See details»
Prilenia - LinkedIn
Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. Our lead asset is Pridopidine, a first-in-class oral ...See details»
Update from Prilenia - Huntington's Disease Youth Organization
Sep 3, 2024 In the meantime, Prilenia will continue having discussions with the U.S. Food and Drug Administration (FDA) and other regulatory agencies about a potential path forward for …See details»
Prilenia - Funding, Financials, Valuation & Investors - Crunchbase
Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. New. Resources. ... How much funding has this …See details»
Prilenia - Contacts, Employees, Board Members, Advisors & Alumni
Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. ... Experience the new Crunchbase, powered by AI . …See details»
Prilenia Expands Leadership Team, Appoints Anne Sullivan as Chief ...
Sep 29, 2022 Prilenia represents an organization truly committed to scientific rigor as well as to people living with serious neurological diseases, like. Prilenia Therapeutics B.V. , a clinical …See details»
Prilenia Company Profile - Office Locations, Competitors ... - Craft
Prilenia is a biotechnology company developing treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a drug candidate with a potential …See details»
Prilenia eyes 2025 launch for Huntington’s drug pridopidine
3 days ago Prilenia Therapeutics is planning to file its Huntington’s disease therapy pridopidine in the EU, despite mixed results in a phase 3 trial. Pridopidine is an oral agonist of the S1R …See details»
Prilenia Enters into a Collaboration and License Agreement with …
4 days ago NAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)-- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to …See details»
Prilenia - Huntington's Disease Society of America
Company Description Prilenia is a clinical late-stage company led by Michael Hayden, MD, PhD focused on developing new treatments for neurodegenerative disorders. Prilenia’s lead asset, …See details»
Prilenia: a potential new treatment for Huntington’s Disease & ALS
Nov 3, 2021 Prilenia is a clinical stage biotech startup founded in 2018 with the purpose of improving the lives of patients and their families by developing treatments for …See details»
Ferrer nabs European rights for ALS asset in €500M pact
4 days ago Prilenia will retain full rights to the oral sigma-1 receptor agonist in North America, Japan and the Asia-Pacific region. Ferrer is paying Prilenia 80 million euros upfront, with up to …See details»
Prilenia Enters into a Collaboration and License Agreement with …
4 days ago NAARDEN, Netherlands & WALTHAM, Mass. — Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and …See details»
Prilenia’s Pridopidine for Huntington’s Disease Accepted for …
Sep 3, 2024 Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and …See details»
Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD …
PROOF-HD is the only late-stage study in Huntington’s disease targeting clinical progression; topline results expected in early Q2 2023 Prilenia Therapeutics B.V., a clinical stage …See details»
Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD …
Mar 28, 2023 HSG Clinical Research, Inc., a wholly owned subsidiary of the HSG, is a full-service clinical research organization that specializes in conducting HD trials. The HSG also …See details»
Prilenia has shared a community letter announcing that they plan …
When Marjorie Guthrie founded our organization in 1967, her vow was to “do something” about this devastating disease. Today we continue her legacy by bringing together the entire …See details»
Prilenia signs deal for former Teva ALS drug worth up to €500m
2 days ago Prilenia has 50 employees, 12 of whom are in Israel, and the proceeds from the commercialization agreement will allow it to expand. In 2020, Prilenia raised $62.5 million led …See details»